Bavarian Nordic A/S (Bavarian)

Oncology Corporate Profile

HQ Location

Hejreskovvej 10A
DK-3490 Kvistg?_rd, Denmark

Company Description

Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVACA, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ProstvacĀ® / rilimogeneimmunotherapyProstate cancerIIIBristol-Myers Squibb
CV301 (+ nivolumab)immunotherapyNon Small Cell Lung Cancer (NSCLC)II
ProstvacĀ® / rilimogene (+ ipilimumab)immunotherapyProstate cancerIIBristol-Myers Squibb
MVA-BN BrachyuryimmunotherapyVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display